Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
76.21
-3.22 (-4.05%)
Nov 12, 2026, 12:49 PM EST - Market open
Tempus AI Revenue
Tempus AI had revenue of $411.54M in the quarter ending September 30, 2026, with 23.14% growth. This brings the company's total for the last twelve months to $1.51B, up 36.56% year-over-year. In the year 2025, Tempus AI had annual revenue of $1.27B with 83.41% growth. That makes Tempus AI the 5,972nd largest company in the world by revenue and 1,505th in the United States.
Revenue (ttm)
$1.51B
Revenue Growth
+36.56%
P/S Ratio
9.31
Revenue / Employee
$397,197
Employees
3,800
Market Cap
13.90B
Revenue by Segment
- Genomics 955.38M 75.1%
- Data and Services 316.41M 24.9%
Fiscal year ended Dec 31, 2025 See the full Tempus AI breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27B | 578.39M | 83.41% |
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | 62.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BrightSpring Health Services | 15.25B |
| Veeva Systems | 3.46B |
| Privia Health Group | 2.43B |
| HealthEquity | 1.36B |
| Waystar Holding | 1.26B |
| Omnicell | 1.24B |
| Hinge Health | 800.82M |
| Doximity | 661.58M |
TEM News
- 1 day ago - Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting - Business Wire
- 2 days ago - Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer - PRNewsWire
- 2 days ago - SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer - PRNewsWire
- 9 days ago - Tempus AI price target raised to $120 from $100 at Mizuho - TheFly
- 9 days ago - Tempus AI price target raised to $92 from $80 at Cantor Fitzgerald - TheFly
- 9 days ago - Tempus AI price target raised to $100 from $80 at BTIG - TheFly
- 9 days ago - Tempus AI price target raised to $89 from $73 at Freedom Capital - TheFly
- 9 days ago - Tempus AI price target raised to $92 from $85 at Baird - TheFly